Reveris Therapeutics is dedicated to discovering and developing targeted therapeutics that interfere with non-oncogene addiction. Non-oncogene addiction represents an exciting window of opportunity for the development of novel cancer therapeutics that promise to be both highly effective and predictably safer than current standards of care. While tumor cells commonly rely on oncogenic signaling pathways for their growth and survival, these oncogenic pathways often become addicted to non-oncogenic proteins to support their function. Proteins participating in non-oncogene addiction typically do not possess genetic mutations and may or may not be overexpressed. Importantly, because these non-oncogenic proteins are not required for normal cell survival they have tremendous potential as safe and effective targets.
Our Disease Focus
One particularly aggressive breast cancer subtype is triple negative breast cancer (TNBC), which accounts for approximately 15-20% of all breast cancer diagnoses. TNBC is associated with poor clinical outcomes due to high rates of relapse and death compared with other breast cancer subtypes, and is more likely to occur in younger women and African Americans. Because no targeted therapies are currently approved for TNBC, the only current treatment options are tumor resection and systemic chemotherapy. These limited treatment options highlight an outstanding, unmet clinical need for new therapeutic approaches to TNBC.
Reveris is developing small molecule inhibitors in collaboration with a team of highly experienced and accomplished scientists within the UNC’s Schools of Medicine, Lineberger Comprehensive Cancer Center, Pharmacy and Center for Integrative Chemical Biology and Drug Discovery.